Amarin reported $-28307000 in Operating Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
DBV Technologies DBVT:US -16771000 3.29M
Abbvie ABBV:US $ 4717M 357M
Aerie Pharmaceuticals AERI:US $ -33.64M 85.38M
Alnylam Pharmaceuticals ALNY:US $ -146.73M 47.83M
Amarin AMRN:US $ -28.31M 44.44M
AstraZeneca AZN:LN 878M 1.17B
Biocryst Pharmaceuticals BCRX:US $ -49.96M 53.62M
Epizyme EPZM:US $ -50926000 360K
Esperion Therapeutics ESPR:US $ -42989000 12.64M
GlaxoSmithKline GSK:LN 2.8B 1.91B
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Heron Therapeutics HRTX:US $ -62.92M 9.39M
Intercept Pharmaceuticals ICPT:US $ -10.27M 10.59M
JAZZ PHA JAZZ:US $ 87.55M 38.17M
Nektar Therapeutics NKTR:US $ -112.91M 0.69M
Novartis NOVN:VX 2.85B 290M
Teva Pharmaceutical Industries TEVA:US $ -713M 791M